Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes

BACKGROUND: Omarigliptin is a potent, selective, oral dipeptidyl peptidase 4 (DPP4) inhibitor with a half-life that allows weekly dosing. Inflammation or insulin resistance might be pathological mediators of cardiovascular events in patients with type 2 diabetes. METHODS: Whether omarigliptin has an...

Descripción completa

Detalles Bibliográficos
Autor principal: Hattori, Sachiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092436/
https://www.ncbi.nlm.nih.gov/pubmed/32211075
http://dx.doi.org/10.1186/s13098-020-00533-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092436/
https://www.ncbi.nlm.nih.gov/pubmed/32211075
http://dx.doi.org/10.1186/s13098-020-00533-3

Ejemplares similares